- Email: [email protected]
Dropsordry supplementation decreases nighttime urinary episodes in perimenopause with Urinary Incontinence. Clinical study
e72
Abstracts / European Journal of Obstetrics & Gynecology and Reproductive Biology 206 (2016) e1–e127
http://dx.doi.org/10.1016/j.ejogrb.2016.07.199
was a 96,2% of subjective satisfaction and a 85.8% objective score in the improvement of quality of life. Conclusion: The combination of High genistin isoflavones and pumpkin seed pyrogallol in Dropsordry tablets seems to be a safe and highly effective supplementation for the relieve of the urinary incontinence symptoms and a better quality of life in perimenopause women.
Hormonal therapy in breast and gynaecological cancers
http://dx.doi.org/10.1016/j.ejogrb.2016.07.200
management of obstetric haemorrhage. Implementation of a specific proforma may be warranted to improve documentation during a major obstetric haemorrhage event. A quantitative approach to estimating blood loss, involving volume and weight assessment, should be considered in all maternity units.
Poster Presentation Efficacy of Dropsordry supplementation on Urinary Incontinence in perimenopause ˜ 1,∗ , C. Lozano 1 , L. De los Jose Angel Maranón 1 Santos , L. Martínez-Campesino 1 , E. Caballero-Garrido 2 , F. Galán-Estella 3 1
Tradichem Innovation Center, Faraday 7, Lab 02, Edificio Claid, Parque Cientifico de Madrid, 28049, Spain 2 Dep. Neurosurgery, University of New Mexico, 1100 Yale Blvd., 87131 Alburquerque, NM, USA 3 Departamento de Quimica Anaítica y Análisis Instrumental, Universdad Autónoma de Madrid, 28049, Spain ˜ E-mail address: [email protected] (J.A. Maranón). Urinary incontinence (UI) is a significant health problem with considerable social and economic impact. An estimated 30% of women aged 30–60 years old have urinary incontinence (UI), while more than 50% of community-dwelling older women have the condition. Stress urinary incontinence and overactive bladder are the common types of incontinence. The prevalence of stress and mixed (stress and urge) incontinence is higher than urge incontinence, but the latter is more likely to require treatment. In women, moderate and severe have a prevalence ranging from about 12% to 17% The objectives of this study was to examine the effect of the supplementation of tablets containing Dropsordry in women with urge urinary incontinence (UUI). Dropsordry is a novel active containing phytoestrogens from SOLGEN, the high genistin soy bean extract and pyrogallol plus polyphenols from standarized pumpkin seed extract. The study was a single-center, not randomiized open prospective, study. 82 women with urinary incontinence ≥45 years were enrolled in this study (45–62 y. old age. Mean 52 y old). Items related to UI symptoms, were previously collected (T0) and these items were reviewed at the final of the study – 8 weeks. (T2). The presence of UI was previously diagnosed using the International Continence Society standards (ICS). Relationships between presence of UI and potential related factors as diabetes were also explored. Daily urinary test control was performed during the 8 weeks of treatment. Daily dosage was 1 g/day (500 mg twice per day) from 0 to 4 week (T1), following a 500 mg/day daily intake from 4 to 8 week (T2). After eight weeks of treatment, the urgency grade score was reduced a 24.7%. The total urge episodes was reduced a 46%. Surprisingly there was no a significant change in daytime urinations (<5%), however nocturia was reduced a 69.35%. Strenght Urinary Incontinence (SUI) was also tested showing a remarkably 52.17% reduction. Moreover the use of daily pantyliners was reduced a 66.25%. In addition, it was performed a panel test survey with quests when subjects of the study were enrolled (T0) and the same quests was performed after 8 weeks of supplementation (T2). 100% of the enrolled women fulfilled the ICIQ-SF quest (Spanish versión) and they were also questioned about the effects they noticed in response to taking the supplement and the change in quality of life. Interestingly no side effects were reported. There
Hormonal therapy in breast and gynaecological cancers Poster Presentation Dropsordry supplementation decreases nighttime urinary episodes in perimenopause with Urinary Incontinence. Clinical study ˜ 1,2,3,∗ , C. Lozano 1 , L. Jose Angel Maranón Martínez-Campesino 1 , L. de Los Santos 1 , E. Caballero-Garrido 2 , F. Galán-Estella 3 1 Tradichem Innovation Center, Faraday 7, Lab 02, Edificio Claid, Parque Cientifico de Madrid, 28049, Spain 2 Dep. Neurosurgery, University of New Mexico, 1100 Yale Blvd., 87131 Alburquerque, NM, USA 3 Departamento de Quimica Anaítica y Análisis Instrumental, Universdad Autónoma de Madrid, 28049, Spain ˜ E-mail address: [email protected] (J.A. Maranón).
Nocturia is a frequent symptom among women complaining of urinary incontinence (UI). The most common urological conditions causing nocturia in elderly is perimenopause. The goal of the study was to examine the effect of Dropsordry on nighttime urinary episodes in perimenopause women with UI. Dropsordry is a novel compounding containing phytoestrogens from SOLGEN isoflavones, and pyrogallol from standarized pumpkin seed extract. A 8 weeks single-center, prospective, open label, not alleatorized, study was conducted in 30 Spanish women. 50 women were enrolled (45–62 y. old). Items related to UI symptoms, were collected (T0). The presence of UI was previously diagnosed using the ICS standards. Relationships between UI and potential related factors were also explored. 100% of the enrolled women fulfilled the ICIQ-SF quest. Two tablets containing 500 mg of Dropsordry were supplemented during the first 4 weeks (T1). From 5th to 8th week (T2) a solely tablet containing 500 mg of Drospsrdy was supplemented. Daily records of micturitions at day at night were carried out. Comparison with baseline demonstrated a statistically significant in nighttime urinary episodes. A remarkable 69% reduction of nocturia was verified at the end of the study. Furthermore it was observed a significant 67% reduction in panty liner uses. No side effects were reported Dropsordry supplementation seems a safe and a effective strategy for reducing urinary incontinence episodes in perimenopause women. 92% of the women subject of the study refers and overall improvement in the quality of life. http://dx.doi.org/10.1016/j.ejogrb.2016.07.201
Abstracts / European Journal of Obstetrics & Gynecology and Reproductive Biology 206 (2016) e1–e127
http://dx.doi.org/10.1016/j.ejogrb.2016.07.199
was a 96,2% of subjective satisfaction and a 85.8% objective score in the improvement of quality of life. Conclusion: The combination of High genistin isoflavones and pumpkin seed pyrogallol in Dropsordry tablets seems to be a safe and highly effective supplementation for the relieve of the urinary incontinence symptoms and a better quality of life in perimenopause women.
Hormonal therapy in breast and gynaecological cancers
http://dx.doi.org/10.1016/j.ejogrb.2016.07.200
management of obstetric haemorrhage. Implementation of a specific proforma may be warranted to improve documentation during a major obstetric haemorrhage event. A quantitative approach to estimating blood loss, involving volume and weight assessment, should be considered in all maternity units.
Poster Presentation Efficacy of Dropsordry supplementation on Urinary Incontinence in perimenopause ˜ 1,∗ , C. Lozano 1 , L. De los Jose Angel Maranón 1 Santos , L. Martínez-Campesino 1 , E. Caballero-Garrido 2 , F. Galán-Estella 3 1
Tradichem Innovation Center, Faraday 7, Lab 02, Edificio Claid, Parque Cientifico de Madrid, 28049, Spain 2 Dep. Neurosurgery, University of New Mexico, 1100 Yale Blvd., 87131 Alburquerque, NM, USA 3 Departamento de Quimica Anaítica y Análisis Instrumental, Universdad Autónoma de Madrid, 28049, Spain ˜ E-mail address: [email protected] (J.A. Maranón). Urinary incontinence (UI) is a significant health problem with considerable social and economic impact. An estimated 30% of women aged 30–60 years old have urinary incontinence (UI), while more than 50% of community-dwelling older women have the condition. Stress urinary incontinence and overactive bladder are the common types of incontinence. The prevalence of stress and mixed (stress and urge) incontinence is higher than urge incontinence, but the latter is more likely to require treatment. In women, moderate and severe have a prevalence ranging from about 12% to 17% The objectives of this study was to examine the effect of the supplementation of tablets containing Dropsordry in women with urge urinary incontinence (UUI). Dropsordry is a novel active containing phytoestrogens from SOLGEN, the high genistin soy bean extract and pyrogallol plus polyphenols from standarized pumpkin seed extract. The study was a single-center, not randomiized open prospective, study. 82 women with urinary incontinence ≥45 years were enrolled in this study (45–62 y. old age. Mean 52 y old). Items related to UI symptoms, were previously collected (T0) and these items were reviewed at the final of the study – 8 weeks. (T2). The presence of UI was previously diagnosed using the International Continence Society standards (ICS). Relationships between presence of UI and potential related factors as diabetes were also explored. Daily urinary test control was performed during the 8 weeks of treatment. Daily dosage was 1 g/day (500 mg twice per day) from 0 to 4 week (T1), following a 500 mg/day daily intake from 4 to 8 week (T2). After eight weeks of treatment, the urgency grade score was reduced a 24.7%. The total urge episodes was reduced a 46%. Surprisingly there was no a significant change in daytime urinations (<5%), however nocturia was reduced a 69.35%. Strenght Urinary Incontinence (SUI) was also tested showing a remarkably 52.17% reduction. Moreover the use of daily pantyliners was reduced a 66.25%. In addition, it was performed a panel test survey with quests when subjects of the study were enrolled (T0) and the same quests was performed after 8 weeks of supplementation (T2). 100% of the enrolled women fulfilled the ICIQ-SF quest (Spanish versión) and they were also questioned about the effects they noticed in response to taking the supplement and the change in quality of life. Interestingly no side effects were reported. There
Hormonal therapy in breast and gynaecological cancers Poster Presentation Dropsordry supplementation decreases nighttime urinary episodes in perimenopause with Urinary Incontinence. Clinical study ˜ 1,2,3,∗ , C. Lozano 1 , L. Jose Angel Maranón Martínez-Campesino 1 , L. de Los Santos 1 , E. Caballero-Garrido 2 , F. Galán-Estella 3 1 Tradichem Innovation Center, Faraday 7, Lab 02, Edificio Claid, Parque Cientifico de Madrid, 28049, Spain 2 Dep. Neurosurgery, University of New Mexico, 1100 Yale Blvd., 87131 Alburquerque, NM, USA 3 Departamento de Quimica Anaítica y Análisis Instrumental, Universdad Autónoma de Madrid, 28049, Spain ˜ E-mail address: [email protected] (J.A. Maranón).
Nocturia is a frequent symptom among women complaining of urinary incontinence (UI). The most common urological conditions causing nocturia in elderly is perimenopause. The goal of the study was to examine the effect of Dropsordry on nighttime urinary episodes in perimenopause women with UI. Dropsordry is a novel compounding containing phytoestrogens from SOLGEN isoflavones, and pyrogallol from standarized pumpkin seed extract. A 8 weeks single-center, prospective, open label, not alleatorized, study was conducted in 30 Spanish women. 50 women were enrolled (45–62 y. old). Items related to UI symptoms, were collected (T0). The presence of UI was previously diagnosed using the ICS standards. Relationships between UI and potential related factors were also explored. 100% of the enrolled women fulfilled the ICIQ-SF quest. Two tablets containing 500 mg of Dropsordry were supplemented during the first 4 weeks (T1). From 5th to 8th week (T2) a solely tablet containing 500 mg of Drospsrdy was supplemented. Daily records of micturitions at day at night were carried out. Comparison with baseline demonstrated a statistically significant in nighttime urinary episodes. A remarkable 69% reduction of nocturia was verified at the end of the study. Furthermore it was observed a significant 67% reduction in panty liner uses. No side effects were reported Dropsordry supplementation seems a safe and a effective strategy for reducing urinary incontinence episodes in perimenopause women. 92% of the women subject of the study refers and overall improvement in the quality of life. http://dx.doi.org/10.1016/j.ejogrb.2016.07.201